Jan 13, 2020 / 06:30PM GMT
Christopher Thomas Schott - JP Morgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Teva today. From the company, we have KÃ¥re Schultz, the company's President and CEO. After Chorus presentation, we're going to go to a breakout session, which is in the Olympic Room around the corner. And with that, I'll turn it over to KÃ¥re.
KÃ¥re Schultz - Teva Pharmaceutical Industries Limited - President, CEO & Director
Good morning, everybody. It's a pleasure to be here. We will be talking about the future. And in that connection, I will recommend you to take a look at this. I won't go through it. So we'll move to the next slide.
Now it's a real pleasure to be here. It's -- 2 years ago that I was here for the first time as CEO of Teva, and I can see a few of you that were there. And back then, we had a pretty dramatic situation. We had a debt of $34 billion. We had CoPaxone that have gone off-patent and had generic competition in the U.S., and
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers